Abcam, ab258656, Human SEC16A (SEC16) knockout HeLa cell lysate

Size: 1Kit
SEC16A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SEC16A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SEC16A also known as SEC16 is an important component in the secretory pathway specifically in vesicle trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus. This protein plays a significant role in the assembly of coat protein complex II (COPII)-coated vesicles acting as a scaffold for other components. SEC16A has a molecular mass of approximately 240 kDa. It is broadly expressed in various tissues with notable expression in cells with high secretory activity.
Biological function summary
Functions of SEC16A are critical in maintaining ER exit sites (ERES) where the budding of COPII vesicles occurs. It localizes to these ERES facilitating the formation of transport vesicles. SEC16A does not work alone; it interacts with several other proteins to form a functional multi-protein complex associated with this vesicle trafficking process. These interactions ensure the efficient transport of proteins and lipids necessary for cellular homeostasis and secretion.
Pathways
SEC16A integrates into the COPII-mediated vesicle formation pathway pivotal for protein sorting and transportation. This protein collaborates closely with the SAR1 SEC23 SEC24 SEC13 and SEC31 proteins through the vesicle formation cycle. Besides its role in COPII assembly SEC16A also contributes to the regulation of ER-Golgi transport influencing the growth factor signaling pathways that depend on the accurate delivery of their receptor components to the cell surface.
Disruptions in the function of SEC16A links to conditions like Anderson-Fabry disease and congenital disorders of glycosylation. Abnormal vesicle trafficking due to SEC16A impairment can lead to an accumulation of metabolites or misfolded proteins that disrupt cellular function. SEC16A's relationship with proteins involved in lipid metabolism and glycosylation supports the role in these disorders. Understanding the behaviour of SEC16A in these contexts may contribute to targeted therapeutic strategies.